CGON Relative Valuation
CGON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CGON is overvalued; if below, it's undervalued.
Historical Valuation
CG Oncology Inc (CGON) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4209.06 is considered Overvalued compared with the five-year average of -17.70. The fair price of CG Oncology Inc (CGON) is between 19.10 to 38.34 according to relative valuation methord. Compared to the current price of 41.93 USD , CG Oncology Inc is Overvalued By 9.37%.
Relative Value
Fair Zone
19.10-38.34
Current Price：41.93
9.37%
Overvalued
-15.37
PE
1Y
3Y
5Y
-11.87
EV/EBITDA
CG Oncology Inc. (CGON) has a current EV/EBITDA of -11.87. The 5-year average EV/EBITDA is -13.71. The thresholds are as follows: Strongly Undervalued below -26.74, Undervalued between -26.74 and -20.23, Fairly Valued between -7.20 and -20.23, Overvalued between -7.20 and -0.68, and Strongly Overvalued above -0.68. The current Forward EV/EBITDA of -11.87 falls within the Historic Trend Line -Fairly Valued range.
-11.34
EV/EBIT
CG Oncology Inc. (CGON) has a current EV/EBIT of -11.34. The 5-year average EV/EBIT is -13.72. The thresholds are as follows: Strongly Undervalued below -26.76, Undervalued between -26.76 and -20.24, Fairly Valued between -7.20 and -20.24, Overvalued between -7.20 and -0.68, and Strongly Overvalued above -0.68. The current Forward EV/EBIT of -11.34 falls within the Historic Trend Line -Fairly Valued range.
4209.06
PS
CG Oncology Inc. (CGON) has a current PS of 4209.06. The 5-year average PS is 3361.84. The thresholds are as follows: Strongly Undervalued below 947.71, Undervalued between 947.71 and 2154.78, Fairly Valued between 4568.90 and 2154.78, Overvalued between 4568.90 and 5775.96, and Strongly Overvalued above 5775.96. The current Forward PS of 4209.06 falls within the Historic Trend Line -Fairly Valued range.
-20.30
P/OCF
CG Oncology Inc. (CGON) has a current P/OCF of -20.30. The 5-year average P/OCF is -13.12. The thresholds are as follows: Strongly Undervalued below -33.27, Undervalued between -33.27 and -23.19, Fairly Valued between -3.05 and -23.19, Overvalued between -3.05 and 7.03, and Strongly Overvalued above 7.03. The current Forward P/OCF of -20.30 falls within the Historic Trend Line -Fairly Valued range.
-16.48
P/FCF
CG Oncology Inc. (CGON) has a current P/FCF of -16.48. The 5-year average P/FCF is -17.75. The thresholds are as follows: Strongly Undervalued below -28.31, Undervalued between -28.31 and -23.03, Fairly Valued between -12.47 and -23.03, Overvalued between -12.47 and -7.19, and Strongly Overvalued above -7.19. The current Forward P/FCF of -16.48 falls within the Historic Trend Line -Fairly Valued range.
CG Oncology Inc (CGON) has a current Price-to-Book (P/B) ratio of 4.76. Compared to its 3-year average P/B ratio of 3.27 , the current P/B ratio is approximately 45.45% higher. Relative to its 5-year average P/B ratio of 3.27, the current P/B ratio is about 45.45% higher. CG Oncology Inc (CGON) has a Forward Free Cash Flow (FCF) yield of approximately -3.47%. Compared to its 3-year average FCF yield of -3.32%, the current FCF yield is approximately 4.66% lower. Relative to its 5-year average FCF yield of -3.32% , the current FCF yield is about 4.66% lower.
4.76
P/B
Median3y
3.27
Median5y
3.27
-3.47
FCF Yield
Median3y
-3.32
Median5y
-3.32
Competitors Valuation Multiple
The average P/S ratio for CGON's competitors is 840.84, providing a benchmark for relative valuation. CG Oncology Inc Corp (CGON) exhibits a P/S ratio of 4209.06, which is 400.58% above the industry average. Given its robust revenue growth of 3774.42%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CGON increased by 41.17% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 43.00K to 1.67M.
The secondary factor is the Margin Expansion, contributed -94.46%to the performance.
Overall, the performance of CGON in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
Frequently Asked Questions
Is CG Oncology Inc (CGON) currently overvalued or undervalued?
CG Oncology Inc (CGON) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4209.06 is considered Overvalued compared with the five-year average of -17.70. The fair price of CG Oncology Inc (CGON) is between 19.10 to 38.34 according to relative valuation methord. Compared to the current price of 41.93 USD , CG Oncology Inc is Overvalued By 9.37% .
What is CG Oncology Inc (CGON) fair value?
CGON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CG Oncology Inc (CGON) is between 19.10 to 38.34 according to relative valuation methord.
How does CGON's valuation metrics compare to the industry average?
The average P/S ratio for CGON's competitors is 840.84, providing a benchmark for relative valuation. CG Oncology Inc Corp (CGON) exhibits a P/S ratio of 4209.06, which is 400.58% above the industry average. Given its robust revenue growth of 3774.42%, this premium appears sustainable.
What is the current P/B ratio for CG Oncology Inc (CGON) as of Jan 08 2026?
As of Jan 08 2026, CG Oncology Inc (CGON) has a P/B ratio of 4.76. This indicates that the market values CGON at 4.76 times its book value.
What is the current FCF Yield for CG Oncology Inc (CGON) as of Jan 08 2026?
As of Jan 08 2026, CG Oncology Inc (CGON) has a FCF Yield of -3.47%. This means that for every dollar of CG Oncology Inc’s market capitalization, the company generates -3.47 cents in free cash flow.
What is the current Forward P/E ratio for CG Oncology Inc (CGON) as of Jan 08 2026?
As of Jan 08 2026, CG Oncology Inc (CGON) has a Forward P/E ratio of -15.37. This means the market is willing to pay $-15.37 for every dollar of CG Oncology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CG Oncology Inc (CGON) as of Jan 08 2026?
As of Jan 08 2026, CG Oncology Inc (CGON) has a Forward P/S ratio of 4209.06. This means the market is valuing CGON at $4209.06 for every dollar of expected revenue over the next 12 months.